Probiotics Impact Intestinal Microbiota in Colon Cancer Patients.
The research shows probiotic intervention can positively alter and modify intestinal microbiota in patients with colon cancer.
A recent research study conducted by the Sahlgrenska Academy at the University of Gothenburg in Gothenburg, Sweden, in collaboration with DuPont Nutrition & Health yielded results demonstrating that probiotic intervention can alter and modify intestinal microbiota in patients with colon cancer.
The study was based on this principle: the human gut microbiota contributes to metabolism, interacts with the immune system and protects against pathogens, so it has the potential to substantially impact overall health and well-being. What defines a healthy microbiome can differ widely for individuals, but recent studies have shown that the gut microbiome is often dysbiotic, or altered from its normal stable state, in diseases such as gastrointestinal disorders, cancer, obesity, and metabolic syndrome. Recent advances in the sequencing technologies used to characterize the microbiome have led to an extensive investment in research focused on the discovery of new therapeutic strategies based on manipulation of the microbiome.
The key finding in the DuPont-backed research study was that the composition and diversity of the microbiota were altered in the tumor tissue and surrounding mucosa in biopsy samples taken from colon cancer patients when compared to non-cancer patients. This colon-cancer associated microbiota was modified by probiotic intervention and characterized by an increase of bacteria known to produce butyrate. The anti-inflammatory benefits of butyrate for colon health are well-documented, and it also has been shown to suppress the growth of colon cancer cells.
“Colorectal cancer (CRC) is one of the top three cancers diagnosed globally each year, and the risk of colorectal cancer is strongly correlated to lifestyle factors such as diet,” said Ashley Hibberd, staff associate investigator, DuPont Nutrition & Health. “The results of our study show that the risk component from the diet may be mediated by the microbiota and that the specific probiotic strains used in this study have the potential to support the microbiota in a beneficial way.”
Probiotic strains Bifidobacterium animalis subsp. lactis Bl 04 and Lactobacillusacidophilus NCFM were manufactured into a protective matrix. These strains were chosen for this study because NCFM was previously shown to suppress colonic tumor growth in mice and reduce the level of carcinogenic metabolites in the human intestine. Bl-04 is known to have immunomodulation properties. The ProBion matrix was chosen as it provided the possibility to design an adequate dose-response profile necessary for clinical documentation.
“The CRC-associated microbiota is being continuously defined as new biomarkers of CRC are discovered,” said Yvonne Wettergren, Ph.D., the Sahlgrenska Academy at the University of Gothenburg. “The microbial dysbiosis observed in patients with CRC may be manipulated by probiotic bacteria if protected by the ProBion matrix, and the probiotic strains used in this study show promise as a beneficial component of enhancing the microbiome in CRC.”
Los Alamos National Laboratory
99% of your Genes come from your Microbiome. (Healthy Microbiome produces healthy DNA and Visa Versa.)
Our bodies contain roughly ten times more microbial cells than human cells, and we know hardly anything about them.
Metagenomics is the field of genetics concerned with the genomic sequencing of microbial communities containing members that cannot be easily isolated from one another. One such microbial community is the human microbiome, comprising the whole compliment of microorganisms (mostly bacteria) that live on and within human bodies. This state of this microbiome is increasingly being shown to affect our health, including development, metabolism, and hormonal regulation.
Does Parkinson’s Begin in the Gut?
A growing body of evidence links the neurodegenerative disease to the gastrointestinal tract, opening new possibilities for treatment.
It's a well-known risk for cardiovascular disease.
Dr. Michael Miller, a cardiologist, and director of the Center for Preventive Cardiology for the University of Maryland Medical System explains that the study found that stiffness of arteries was more likely to be influenced by gut bacteria than risk factors such as obesity and insulin resistance.
A lack of diversity in healthy bacteria in the gut has been associated with diabetes, obesity, and inflammatory stomach and bowel diseases. Additionally, the researchers pinpointed which microbes were tied to a lower risk of arterial stiffening.
INTRODUCING ADVANCED PRE/PROBIOTIC TECHNOLOGY-X20
Developed by Biochemist Mr. Eric Baer Exclusively For Looking Vibrant
(Patented Enteric Coates Caps NG Probiome Guard have a superior lack of dissolution: Only 6.95% after 120 minutes in pH 1.2 simulated stomach environment.)
Get 10% discount with this promo code: advanced10 (Fee delivery with purchase $100+)